Developing Precision Targeted Therapies Against Cancer
Rakuten Aspyrian, Inc., is a privately funded clinical stage biotechnology company with offices in the USA, Japan and Germany.
Since 2013, Rakuten Aspyrian has been developing new anticancer therapies based on the Photoimmunotherapy platform.
Rakuten Aspyrian plans to become a fully integrated biopharma with research, development, and world-wide commercialization of therapies based on the Photoimmunotherapy platform.
Our long-term objective is to commercialize a number of therapies based on Photoimmunotherapy to treat a broad range of solid tumor types as single agent and in combination with other immunomodulatory agents to generate robust and long lasting anticancer immunological responses.
Rakuten Aspyrian is currently sponsoring a global Phase 3 multicenter clinical study for ASP-1929 to evaluate the efficacy and safety of ASP-1929 in patients with recurrent Head and Neck Cancer and additional Phase 2 studies to evaluate the safety and efficacy of ASP-1929 in patients with other cancer types.
Our Mission Statement
"We are for the cancer patients, to offer them the possibility to battle cancer, with precision-targeted medicines
We create a new way to fight cancer, with uncompromising science, passion and commitment.
Rakuten Aspyrian pursues a future where cancer
is no longer a threat to the patients' lives."*
*ASP-1929 is an experimental therapy and has not been approved by the FDA
Chairman of the Board
Director of the Board
Miguel Garcia-Guzman, Ph.D.
President & CEO
Takashi Toraishi, Ph.D.
President and Representative Director Rakuten Aspyrian Japan, K.K.
Andreas Rose, Dipl.-Ing.
President and Managing Director, Rakuten Aspyrian Europe GmbH
Merrill Biel, M.D., PH.D., F.A.C.S.
Chief Medical Officer
Carlos Garcia, M.S.
Chief Technology Officer
Maria Tello, M.D.
Executive Director of Safety & Pharmacovigilance
Shawn Schaffer, PH.D.
Head of Quality
Agatha Martindale, C.P.A.
Suzane San, M.B.A.
Head of People Operations
Gabriela Velasquez, B.A.
Leader, Talent Acquisition & Development
Abhijit Bhatia, M.S., M.B.A.
Director, Corporate & Business Development
Director of Strategic Planning and Operations, Head of Asia Business Promotion, Rakuten Aspyrian Japan, K.K.
Isaac “Zack” Dye, Esq.
Lola Fong, M.B.A.
Director Clinical Operations
Sandy Bertelsen-Putirka, M.S.
Director Clinical Operations
Takuji Achiwa, M.S.
VP Clinical Development, Rakuten Aspyrian Japan K.K.
Sampsa Kuusiluoma, MSE, CLSSGB.
Manager of Operations, Quality & Regulatory Affairs, Rakuten Aspyrian Europe GmbH
Eileen Sun, Ph.D
Associate Director, Leader of Program Management
Jessica Berrett, M.H.A.
Director of Data Management
Jeff Zhao, PH.D.
Director of Biostatistics
Code of Business Ethics and Conduct
Rakuten Aspyrian’s Code of Business Ethics and Conduct provides guidelines to our directors, officers, employees, and our agents, consultants, and contractors to conduct our business ethically and in strict compliance with all applicable laws, rules, and regulations.
At Rakuten Aspyrian, it’s everyone’s responsibility to follow the Code of Business Ethics and Conduct and comply not only with the word of these policy, but also with its essence and intent. Everyone at Rakuten Aspyrian must:
- Understand and adhere to the Code of Business Ethics and Conduct.
- Follow all applicable laws and regulations.
- Follow all Rakuten Aspyrian policies.
- Seek clarification or guidance when they have a question about the Code of Business Ethics and Conduct or compliance.
- Report a concern when they suspect a violation of the Code of Business Ethics and Conduct.
- Use their good judgment and always act with honesty and integrity and ethics.